Cardiac dysfunction induced by trastuzumab

被引：0

作者：

Campone, M

Bourbouloux, E

Fumoleau, P

机构：

[1] Ctr Rene Gauducheau, F-44805 Nantes, France

[2] Ctr Georges Francois Leclerc, F-21034 Dijon, France

来源：

BULLETIN DU CANCER | 2004年 / 91卷

关键词：

trastuzumab; cardiac toxicity;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Trastuzumab combined to chemotherapy had demonstrated significant improvement of time to progression and survival in metastatic breast cancer patient overexpressing HER-2. Cardiac toxicity was an unexpected side effect. The incidence of cardiac dysfunction was dependent on prior or current anthracycline exposure. The mechanism of action involved for this cardiac toxicity is unclear. We discuss in this article the incidence, the physiopathology, the risk factors, the predictive factors and the patient management and on cardiotoxicity of trastuzumab.

引用

收藏

页码：S166 / S173

页数：8

相关论文

共 33 条

[1] Safety profile of Herceptin (R) as a single agent and in combination with chemotherapy [J].

Baselga, J .

EUROPEAN JOURNAL OF CANCER, 1999, 35 :S324-S324

[2] Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast [J].

Baselga, J ;

Tripathy, D ;

Mendelsohn, J ;

Baughman, S ;

Benz, CC ;

Dantis, L ;

Sklarin, NT ;

Seidman, AD ;

Hudis, CA ;

Moore, J ;

Rosen, PP ;

Twaddell, T ;

Henderson, IC ;

Norton, L .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :737-744

[3]

Behr TM, 2001, NEW ENGL J MED, V345, P995

[4] Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm [J].

Burstein, HJ ;

Harris, LN ;

Marcom, PK ;

Lambert-Falls, R ;

Havlin, K ;

Overmoyer, B ;

Friedlander, RJ ;

Gargiulo, J ;

Strenger, R ;

Vogel, CL ;

Ryan, PD ;

Ellis, MJ ;

Nunes, RA ;

Bunnell, CA ;

Campos, SM ;

Hallor, M ;

Gelman, R ;

Winer, EP .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) :2889-2895

[5] Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy [J].

Cardinale, D ;

Sandri, MT ;

Martinoni, A ;

Borghini, E ;

Civelli, M ;

Lamantia, G ;

Cinieri, S ;

Martinelli, G ;

Fiorentini, C ;

Cipolla, CM .

ANNALS OF ONCOLOGY, 2002, 13 (05) :710-715

[6] Involvement of the neuregulins and their receptors in cardiac and neural development [J].

Carraway, KL .

BIOESSAYS, 1996, 18 (04) :263-266

[7] Myocyte survival pathways and cardiomyopathy: Implications for trastuzumab cardiotoxicity [J].

Chien, KR .

SEMINARS IN ONCOLOGY, 2000, 27 (06) :9-14

[8] Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].

Cobleigh, MA ;

Vogel, CL ;

Tripathy, D ;

Robert, NJ ;

Scholl, S ;

Fehrenbacher, L ;

Wolter, JM ;

Paton, V ;

Shak, S ;

Lieberman, G ;

Slamon, DJ .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648

[9] Retrospective analysis of the safety of Herceptin® immunotherapy in metastatic breast cancer [J].

Cook-Bruns, N .

ONCOLOGY, 2001, 61 :58-66

[10]

Erickson SL, 1997, DEVELOPMENT, V124, P4999

← 1 2 3 4 →